Use of hyaluronic acid as an immunosuppressant
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 11, 2000
Grant Date -
N/A
app pub date -
Sep 27, 1996
filing date -
Sep 28, 1995
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A pharmaceutical formulation of hyaluronic acid is administered to a patient suffering from undesirable T cellactivity. The hyaluronic acid inhibits T cell activity at doses that are well-tolerated by the recipient. Conditions suitable for treatment include graft vs. host disease, graft rejection and certain autoimmune diseases having a T cell component.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully